These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 27754959)

  • 1. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
    Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
    Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma.
    Giovanella L; Fontana M; Keller F; Campenni' A; Ceriani L; Paone G
    Clin Chem Lab Med; 2021 Aug; 59(9):1569-1573. PubMed ID: 33860650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ProGRP AS A NOVEL BIOMARKER FOR THE DIFFERENTIAL DIAGNOSIS OF MEDULLARY THYROID CARCINOMA IN PATIENTS WITH THYROID NODULES.
    Liang X; Zhu J; Cai M; Dai Z; Fang L; Chen H; Yu L; Lin Y; Lin E; Wu G
    Endocr Pract; 2020 May; 26(5):514-522. PubMed ID: 32045291
    [No Abstract]   [Full Text] [Related]  

  • 4. Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma.
    Inaji H; Komoike Y; Motomura K; Higashiyama M; Ohtsuru M; Funai H; Kasugai T; Koyama H
    Oncology; 2000 Aug; 59(2):122-5. PubMed ID: 10971170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the application value of pro-gastrin-releasing peptide in the clinical diagnosis and surgical treatment of medullary thyroid carcinoma.
    Miao Q; Lv X; Luo L; Zhang J; Cai B
    Cancer Med; 2023 Oct; 12(19):19576-19582. PubMed ID: 37754747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
    Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
    Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
    Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
    J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?
    Niederle MB; Scheuba C; Riss P; Selberherr A; Koperek O; Niederle B
    Thyroid; 2020 Jul; 30(7):974-984. PubMed ID: 32056502
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical performance of calcitonin and procalcitonin Elecsys
    Giovanella L; Fontana M; Keller F; Verburg FA; Ceriani L
    Clin Chem Lab Med; 2021 Mar; 59(4):743-747. PubMed ID: 33085633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
    Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
    Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of PET/CT with
    Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
    Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
    Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
    Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
    Zhou Q; Yue S; Cheng Y; Jin J; Xu H
    Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer.
    Kartal Baykan E; Erdoğan M
    Turk J Med Sci; 2021 Apr; 51(2):650-656. PubMed ID: 33128357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medullary thyroid carcinoma].
    Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
    Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
    Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M
    Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay.
    Torsetnes SB; Broughton MN; Paus E; Halvorsen TG; Reubsaet L
    Anal Bioanal Chem; 2014 Apr; 406(11):2733-8. PubMed ID: 24518900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The variable pathologic presentations of medullary and micro-medullary thyroid carcinoma: an institutional experience.
    Samulski TD; Livolsi VA; Montone K; Baloch Z
    Pathol Res Pract; 2014 Mar; 210(3):182-5. PubMed ID: 24440099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.